Show simple item record

dc.contributor.authorSurugiu, Roxana
dc.contributor.authorOlaru, Andrei
dc.contributor.authorHermann, Dirk M
dc.contributor.authorGlavan, Daniela
dc.contributor.authorCatalin, Bogdan
dc.contributor.authorPopa-Wagner, Aurel
dc.date.accessioned2020-01-20T04:46:36Z
dc.date.available2020-01-20T04:46:36Z
dc.date.issued2019
dc.identifier.issn1422-0067
dc.identifier.doi10.3390/ijms20236029
dc.identifier.urihttp://hdl.handle.net/10072/390623
dc.description.abstractFollowing the failure of acute neuroprotection therapies, major efforts are currently made worldwide to promote neurological recovery and brain plasticity in the subacute and post-acute phases of stroke. Currently, there is hope that stroke recovery might be promoted by cell-based therapies. The field of stem cell therapy for cerebral ischemia has made significant progress in the last five years. A variety of stem cells have been tested in animal models and humans including adipose stem cells, human umbilical cord blood-derived mesenchymal stem cells, human amnion epithelial cells, human placenta amniotic membrane-derived mesenchymal stem cells, adult human pluripotent-like olfactory stem cells, human bone marrow endothelial progenitor cells, electrically-stimulated human neuronal progenitor cells, or induced pluripotent stem cells (iPSCs) of human origin. Combination therapies in animal models include a mix of two or more therapeutic factors consisting of bone marrow stromal cells, exercise and thyroid hormones, endothelial progenitor cells overexpressing the chemokine CXCL12. Mechanisms underlying the beneficial effects of transplanted cells include the “bystander” effects, paracrine mechanisms, or extracellular vesicles-mediated restorative effects. Mitochondria transfer also appears to be a powerful strategy for regenerative processes. Studies in humans are currently limited to a small number of studies using autologous stem cells mainly aimed to assess tolerability and side-effects of human stem cells in the clinic.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.publisher.placeSwitzerland
dc.relation.ispartofissue23
dc.relation.ispartofjournalInternational Journal of Molecular Sciences
dc.relation.ispartofvolume20
dc.subject.fieldofresearchOther chemical sciences
dc.subject.fieldofresearchGenetics
dc.subject.fieldofresearchOther biological sciences
dc.subject.fieldofresearchcode3499
dc.subject.fieldofresearchcode3105
dc.subject.fieldofresearchcode3199
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsPhysical Sciences
dc.subject.keywordsBiochemistry & Molecular Biology
dc.subject.keywordsChemistry, Multidisciplinary
dc.titleRecent Advances in Mono- and Combined Stem Cell Therapies of Stroke in Animal Models and Humans
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationSurugiu, R; Olaru, A; Hermann, DM; Glavan, D; Catalin, B; Popa-Wagner, A, Recent Advances in Mono- and Combined Stem Cell Therapies of Stroke in Animal Models and Humans, International Journal of Molecular Sciences, 2019, 20 (23)
dcterms.dateAccepted2019-11-29
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2020-01-19T23:59:53Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2019 The Authors. Licensee MDPI, Basel, Switzerland. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorPopa-Wagner, Aurel


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record